MedTrace Logo

Multicenter CTS Pre-and Post-Transplantation Covid-19 Serum Studies

NCT04694573 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2021-01-19

No results posted yet for this study

Summary

The Covid-19 Serum Study is a prospective case-control study in

1. kidney or liver transplanted patients being hospitalized due to an infection with Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) after transplantation (TX) (POST-TX Covid-19 Serum Study)

or
2. patients receiving kidney or liver transplantation after having had a SARS-CoV-2 infection (PRE-TX Covid-19 Serum Study)

The aim of this study is to evaluate the development of de novo donor specific antibodies (dnDSA) in transplanted patients being hospitalized due to an infection with SARS-CoV-2 (POST-TX Covid-19 Serum Study) as well as in patients receiving kidney or liver transplantation after having had an infection with SARS-CoV-2 prior to transplantation (PRE-TX Covid-19 Serum Study).

Further, the investigators will evaluate possible consequences of having had a SARS-CoV-2 infection prior or after liver or kidney transplantation with regard to graft survival and incidence of graft rejection episodes as well as SARS-CoV-2 specific antibody development after SARS-CoV-2 infection.

Conditions

  • Covid19
  • Kidney Transplant; Complications
  • Kidney Transplant Failure and Rejection
  • Liver Transplant; Complications
  • Liver Transplant Failure and Rejection

Sponsors & Collaborators

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Caner Suesal, Professor · Institute of Immunology Heidelberg

  • Christian Morath, Professor · Department of Nephrology, Heidelberg

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-28
Primary Completion
2021-12-28
Completion
2022-12-28

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04694573 on ClinicalTrials.gov